April 2026—Quest Diagnostics has launched Quest Flow Cytometry MRD for Myeloma, a novel blood test that uses advanced flow cytometry methods to assess measurable residual disease in patients who have myeloma. Quest reports that the test provides sensitivity comparable to next-generation sequencing methods in detecting residual myeloma and features five-day specimen stability. In addition, the test can be used when a baseline aspirate sample is not available.
Quest Diagnostics, 800-222-0446